Posts by Raymond J. March
Raymond J. March is a Research Fellow at the Independent Institute and Assistant Professor of Agribusiness and Applied Economics at North Dakota State University.
FDA Wants More Sunscreen Regulations, but Would Consumers Get Burned?


Attempts to find “the right balance” are more likely to throw the sunscreen market wildly out of balance.

FDA Panel Backs Ketamine-Based Treatment for Depression


Despite its exciting potential, esketamine is receiving significantly more attention for being similar to the street drug ketamine.

Let Competition, Not Politicians, Bring Insulin Prices Down


Evidence suggests that competition, not politicians, would provide the best chance to help diabetics obtain their life-prolonging medication.

Right-to-Try Laws Help Patient with Terminal Brain Cancer


When treatments are unavailable, and prognoses are fatal, the best chance to prolong life is to consider all remaining options.

FDA Approves Record Number of Generic Drugs in 2018


With U.S. drug prices among the highest in the world, generics provide significant financial relief for millions using prescription drugs.

Teen Vaping Is Bad, but the Alternative Is Worse


The FDA’s efforts to reduce teen vaping rates will likely result in worse health outcomes by prompting teens to switch to smoking cigarettes.

Can the FDA Prevent Teens from Vaping?


Epidemics are causes for concern, but before we declare regulation to be the cure, we should question who administers the treatment.

Deregulation Is the Only Cure for High Drug Prices


The FDA’s influence in the prescription drug market remains the largest obstacle to deregulation.

FDA Vaping Regulations Will Do More Harm than Good


Stringent regulations on the e-cigarette market to come.

To Help the Terminally Ill, the FDA Must Deregulate


Right-to-try will never reach its potential without deregulation.

  • Catalyst
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org